Molecular imaging developer Positron has received a nuclear pharmacy license from the Indiana Board of Pharmacy for its manufacturing facility in Crown Point, IN.
The license completes the requirements necessary to amend Positron's Nuclear Regulatory Commission (NRC) license to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the U.S., according to the vendor. Positron said it would begin to produce indium-111 oxyquinoline at the facility for customer evaluation and commercial sale.
